Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation
|
|
- Edwina Cain
- 6 years ago
- Views:
Transcription
1 Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation Carlo Pappone, MD, PhD, FACC EP Director, Villa Maria Hospital Group
2 How many times AF can increase mortality DO MORTALITY REALLY EXIST? 7 2,5 2 1,9 JACC 2006
3 AADS DO THEY WORK? Conversion: variable efficacy and safety in restoring SR AFib prophylaxis: at 1 year 50% of patients will remain sinus Safety: 2-6% at mid-to-long term Source: Revised Guidelines for AFib 2006 AHA/ESC/ACC/Hrbook
4 PIAF, RACE, STAF, AFFIRM, HOT CAFE Mortality equivalent or even worse with AAD Source: Revised Guidelines for AFib 2006 AHA/ESC/ACC/HR
5 RHYTHM VS. RATE ( 02) ABLATION VS. AAD ( 03)
6 2003 ABLATION? INVESTIGATIONAL
7 2010 WHAT IS CHANGED?
8 ATRIAL FIBRILLATION THE COMMON RATIONALE
9 BENEFIT OF THE INTERVENTION No. Pts F/u (mo.) Efficacy PAPPONE ablation drugs % 22% NATALE ablation drugs % 56% ablation drugs % 26% ablation drugs % 23% 1 2 FDA study 3 JAIS4 1 JACC 2006; 2 JAMA 2005; 3 submitted; 4 Circulation 2008
10
11 THE APAF STUDY JACC 2006
12 198 patients enrolled Randomization CPVA N=99 CPVA-F CPVA-A ADT N=99 CPVA-S Flecainide Amiodarone 1 month run-in phase after AAD start CARTO NavX CPVA 8 mm tip 4 mm cool tip Blanking period Follow-up Continuing AAD 1 month 12 months Sotalol
13 PATIENT CHARACTERISTICS CPVA (99) Control Group (99) P Age 55 ± ± Gender (M/F) 69 / / AF episode/year 52 ± ± Duration of AF (years) 6±4 6± LA diameter (mm) 40 ± 6 38 ± Diabetes 5.1% 4% 1.00 Hypercholesterolemia 17% 21% 0.59 Hypertension 56% 57% ± 8 61 ± % 3% 2% 2% 1% 1% 0.22 No of previously ineffective AADs 2±1 2± No of prior cardioversions 2 ±1 2± LV EF Structural heart disease Coronary artery disease Valvular heart disease Congenital heart disease THE APAF TRIAL
14 APAF - OUTCOMES
15 THE FIRST FDA STUDY MULTICENTER, RANDOMIZED Wilber, Pappone, submitted
16 THE FIRST FDA STUDY: CPVA VS. AAD AF Freedom Wilber, Pappone, submitted
17 43% REDO RATE 89% VS 23% Circulation, 2005
18 CPVA ON THE TOP OF AAD 66% vs. 9% 137 patients randomized to ablation and AAD (ablation group) AAD alone (control group)
19 UNMET NEEDS Short-term results of the APAF, CACAF, A4 and FDA studies suggest that AF ablation strategy warrants consideration in selected patients in whom ADT has already failed and maintenance of SR is desired. However, before translating the results of this study into clinical practice, longer follow-up studies are required.
20 THE APAF 2 STUDY 3-YEAR EXTENSION STUDY PRESENTED AT THE 2009 AHA SCIENTIFIC SESSIONS
21 APAF 2 - OBJECTIVE APAF2 is an extension study to evaluate long-term outcome of catheter ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation.
22 APAF 2 - METHODS APAF 2 study: After completion of 1-year follow-up period, patients were offered participation in a 3-year continuation phase and the follow-up was extended to June 2009.
23 APAF 2 METHODS Minimum follow-up 4 years Follow-up visits at 12, 18, 24, 30 and 36 months after randomization At each visit, 12-lead electrocardiogram (ECG), 48-h Holter monitoring, and transthoracic echocardiography Patients were provided with an event monitor to record their rhythm twice a week and whenever they experienced symptoms suggestive of AF
24 APAF 2 - ENDPOINTS Primary endpoint AF/AT freedom after a single procedure off AADs at 4y Secondary endpoints: Redo procedures Crossover AF progression Late complications QoL (SF-36)
25 STUDY FLOW Screened patients (n = 334) Inclusion criteria not met (n = 136) Enrolled patients with paroxysmal AF (n = 198) Randomization CPVA (n = 99) Recurrent AT/AF (n = 4) 2 after index and >1 AAD 2 after redo CPVA and >1 AAD Persistent/permanent AF (n = 1) After redo CPVA and 1 AAD trial Pappone, APAF 2 3 year Sinus rhythm (n = 95) 77 after index CPVA 18 after redo CPVA ADT (n = 99) Sinus rhythm (n = 62) 11 after 1 AAD 01 after >1 AAD 50 after switch to CPVA 11/26 of unablated patients progressed to chronic AF (42%) Recurrent AT/AF (n = 37) 26 after >1 AAD 11 after switch to CPVA 17 persistent AF after >1 AAD 11 permanent AF after >1 AAD
26 CPVA ARM CPVA (n = 99) Recurrent AT/AF (n = 4) 2 after index and >1 AAD 2 after redo CPVA and >1 AAD Persistent/permanent AF (n = 1) After redo CPVA and 1 AAD trial Sinus rhythm (n = 95) 77 after index CPVA 18 after redo CPVA
27 ADT ARM ADT (n = 99) Sinus rhythm (n = 62) 11 after 1 AAD 01 after >1 AAD 50 after switch to CPVA Recurrent AT/AF (n = 37) 26 after >1 AAD 11 after switch to CPVA 17 persistent AF after >1 AAD 11 permanent AF after >1 AAD
28 PRIMARY ENDPOINT 72% VS 12%
29 LONG-TERM ABLATION SUPERIORITY 1.0 log-rank p<0.001 Proportion of AF-free patients 0.9 CPVA ADT 0.1 1y y y 24 Months of Follow-up
30 NEED FOR CROSS OVER DURING F/U The need for crossover increased over f/u
31 RESULTS AFTER CROSS OVER Crossover strikingly works on ADT failure
32 BASELINE CLINICAL CHARACTERISTICS OF CROSSOVER AND NON CROSSOVER PATIENTS No Crossover Crossover LA dilation and frequent AF predict ADT failure and need for ablation
33 COMPARISON OF CROSSOVER PATIENTS WITH AND WITHOUT AT/AF RECURRENCE LA dilation and frequent AF predict CPVA failure after cross over
34 APAF 2 PROGRESSION TO PERSISTENT & PERMANENT AF Persistent AF Ablation halt AF natural history to progress Permanent AF
35 PROGRESSION TO PERSISTENT AF Progression to persistent AF occurred in 17 ADT patients (mean age 54±10, 14 males) and just in one CPVA patient (59 y). Echo data ADT patients showed a marked increase in LA diameters (from 34 to 50 mm and from 38 to 47 ml, p<0.001). E/A ratio increased from 1.25 to 1.7 (p<0.001) LVEF remained unchanged (61% to 59%, p=0.26)
36 PROGRESSION TO PERMANENT AF Persistent AF became permanent AF in 11 of the 17 ADT patients (55 years, 8 males) after 2 AAD trials including amiodarone and multiple unsuccessful electrical cardioversions Echo data LA diameters (from 33.0±4.4 to 51.9±3.65 mm; p<0.001) LA volumes (from 39 to 48 ml, p<0.001) LVEF remained unchanged (61% to 60%, p=0.28)
37 APAF 2 AF PROGRESSION The only patient in the CPVA group who progressed to persistent and then to permanent AF was a 59-year old man with previous myocardial infarction and metabolic syndrome Echo data: LA diameter (from 59 to 65 mm) EF 40% remained unchanged
38 APAF 2 SILENT AF RECURRENCES Silent AF recurrences occurred in many patients on long-term ADT and only in a minority of those who underwent catheter ablation (40% vs 5%)
39 APAF 2 LATE COMPLICATIONS CPVA No late complications were observed either after index/redo procedures or crossover to ablation ADT 33 patients experienced serious intolerable adverse events requiring crossover to ablation Severe bradycardia (12 pts) Amiodarone-induced thyroid dysfunction (15 patients) Amiodarone-induced acute hepatitis (1 pt) Hypotensive wide QRS tachycardia (5 patients) after flecainide and amiodarone.
40 APAF 2 HOSPITALIZATIONS CPVA Hospitalization (2 patients) after an unsuccessful redo procedure for cardioversion ADT Multiple hospitalizations for recurrent paroxysmal (35 patients) or persistent AF (17 patients) for cardioversion and for an acute pulmonary edema (4 patients with persistent AF, diabetes and hypertension).
41 APAF 2 QUALITY OF LIFE BASELINE RFA (n=99) AADs (n=99) Physical functioning 68 (68-68) 75 (62-75) Role physical 65 (62-75) Bodily pain FOLLOW-UP p-value RFA (n=99) AADs (n=99) p-value (75-80)* 62 (50-70)* < (62-75) (75-80)* 62 (50-75)* < (70-75) 75 (62-75) (75-80)* 50 (50-75)* <0.001 General health 62 (50-75) 70 (50-75) (75-80)* 62 (50-75)** <0.001 Vitality 75 (75-75) 75 (70-75) (75-80)* 75 (50-75)* <0.001 Social Functioning 60 (55-60) 60 (59-65) (75-75)* 50 (50-75) <0.001 Role emotional 75 (75-75) 75 (75-75) (75-80)* 62 (50-75)* <0.001 Mental health 63 (63-63) 62 (50-75) (75-80)* 50 (50-50)* <0.001 Despite AAD patients showed better QoL at baseline, all physical and mental scales were in favor of RFA at the final assessment
42 APAF 2 - LIMITATIONS Catheter ablation was performed in a single highly specialized center with extensive experience in catheter ablation of AF The majority of ablated patients were relatively young without structural heart diseases. Therefore, these results cannot be generalized or applied to all AF patient populations Despite these limitations, we believe that the reported results challenge the notion that multiple antiarrhythmic drugs, as single drugs or in combination, should be used life-long in patients with a long history of PAF
43 APAF 2 CONCLUSIONS Catheter ablation maintains over years its striking superiority over ADT in terms of efficacy, morbidity and QoL. Patients on long-term ADT are more likely to progress to persistent/permanent AF than ablated patients These findings justify the early deployment of catheter ablation in patients with symptomatic PAF
44 PERMANENT AF STEPS BEYOND PULMONARY VEIN ABLATION STEPS 1. CPVA 2. ENDO CS 3. SEPTUM 4. LAA 5. EPI CS 6. RIGHT ATRIUM 7. CFE
45 PERMANENT AF SHORT- MID-TERM RESULTS No. Pts F/u (mo.) Efficacy ORAL PAPPONE CAFE3 CPVA % 74% HAISSAGU ERRE1 ablation 12 87% PAPPONE4 Biatrial Ablation 36 87% JCE 2007 Circulation NEJM Submitted 1 2
46 BENEFIT OF THE INTERVENTION Consensus has been reached about ablation efficacy in selected patients Pappone, NEJM 2006
47 THE STEPWISE STRATEGY Goal: organization of a chaotic AF into a single mappable AT or SR (RF cardioversion) Method: progressive substrate ablation to de-complex AF tailored in individual patient
48 PERMANENT AF CLINICAL OUTCOME % R S Biatrial Group CPVA Group F/U months Submitted
49 COMPLICATIONS WHAT S MATTER? Acute complications rate approaching AF intrinsic morbidity/mortality can nullify any mid- to long-term benefit
50 SAFETY IN AN EXPERIENCED CENTER (N=19029) Death 0 (0%) Pericardial effusion 20 (0.23%) Stroke 1 (0.011%) TIA 4 (0.05%) Tamponade 7 (0.08%) Atrial-esophageal fistula 1 (0.012%) PV stenosis 0 (0%) Incisional LA tachycardia 601 (6.99%) Transient ERAF 1166 (17%) * Overall complication rate including post CPVA LA AT 7.30% Major complication rate 0.38% over 8,682 AFib patients treated with CPVA or CPVA-M* Minor complication preventable with the CPVA-M *
51 INCIDENCE OF DEATH ACCORDING TO TYPE OF COMPLICATION. Complication death / overall events Incidence no. % - Tamponade 7/ Atrio-esophageal fistula 2/ Massive pneumonia 2/ Peripheral embolism - Stroke 3/ Myocardial infarction 1/ Torsade de pointes 1/ Septicemia (3 weeks after procedure) 1/ Sudden respiratory arrest 1/ Acute pulmonary vein occlusion of both lateral veins 1/ Internal bleeding 3/ Anaphylaxis 1/ Acute respiratory distress syndrome 1/ Esophageal perforation from intra-operative TEE probe 1/ of R. Cappato Courtesy
52 SUMMARY STANDARDIZATION OF THERAPY Pulmonary Vein Ablation has become the stadard of care
53 You can die of ablation (1/1000) Survey to 0.1% peri-procedure risk 0.3% risk for disabling stroke
54 Matter of patients, of course
55 Success rate Complication rate Safety and Efficacy 100 COMPLICATIONS OF CATHETER ABLATION 90 UNIVERSITY OF MILAN (N=19029) % + Matter of experience, also Pericardial effusion and tamponade Atrial Tachy Year LA maze Ostial CPVA Irrigated Junctional CPVA catheter CPVA-M 2005 Vagal Denervation
56 COMPLICATIONS ABLATION GUIDELINES Be aware of what risk you are incurring to Train also in complication detection and management
57 SUCCESS IS NOT THE SAME ANYWHERE
58 AF Freedom High enrolling, 98% FDA STUDY Low enrolling, 48% Wilber, Pappone, submitted
59 CONCLUSIONS AF is associated with an excess mortality which can t be lowered with AAD Catheter ablation is superior to AAD after 1 year, results are maintained longterm (3 YEARS) High complication rate can impair any longterm benefit With both depending from learning curve
60 To bridge the gap between promise and practice appropriately powered randomized controlled MORTALITY trials will be needed (CABANA NEEDED)
61 AF OTHER THINKING
62 AF OTHER THINKING
63 IF WE ALL AGREE, THE SCIENTIFIC PROGRESS WILL NEVER MOVE FORWARD
Ablazione della fibrillazione atriale: dubbi presenti e prospettive future
Ablazione della fibrillazione atriale: dubbi presenti e prospettive future Carlo Pappone, MD, PhD, FACC Cardiac Pacing & Electrophysiology Department, Director Villa Maria Group, Italy Atrial Fibrillation
More informationCATHETER ABLATION FOR ATRIAL FIBRILLATION WHEN and HOW
CATHETER ABLATION FOR ATRIAL FIBRILLATION WHEN and HOW Carlo Pappone, MD, PhD, FACC San Raffaele University Hospital, Milan, Italy ATRIAL FIBRILLATION FOR CLINICIANS FIRST DETECTED PAROXYSMAL PERMANENT
More informationΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital
ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital Rate control versus Rhythm control for Atrial Fibrillation AFFIRM N Engl J Med 2002;347:1825-33
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationJay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center
Jay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center A-Fib Facts Yes, you may be able to blame your parents It is more of a nuisance than a
More informationAtrial Fibrillation 2009
Atrial Fibrillation 2009 Michael Glikson, MD Director of Pacing & Electrophysiology Leviev Heart Center Sheba medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center Rhythm vs rate control
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationAtrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
More informationCatheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes
Catheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes Francis Marchlinski, MD Richard T and Angela Clark President s Distinguished Professor Director Cardiac Electrophysiolgy University
More informationAtrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States
Atrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States Srinivas R. Dukkipati, MD Co-Director, Cardiac Arrhythmia Service The Mount
More informationTreating Atrial Fibrillation. Richard Schilling. St Bartholomew's Hospital, Queen Mary s University of London
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary s University of London AF burden Framingham Lifetime risk of developing AF = 25% Mortality: SMR =1.9 1.5 NHS audit 1%
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationA Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.08.037
More informationΚατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.
Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» Rhythm control antiarrhythmic drugs vs catheter ablation Summary
More informationRADAR-AF Trial. A Randomized Multicenter Comparison of Radiofrequency Catheter Ablation of Drivers vs. Circumferential Pulmonary Vein
RADAR-AF Trial A Randomized Multicenter Comparison of Radiofrequency Catheter Ablation of Drivers vs. Circumferential Pulmonary Vein Isolation in Patients with Atrial FibRillation Felipe Atienza, MD, PhD,
More informationCatheter Ablation of Atrial Fibrillation
Cardiology Update 2011 Catheter Ablation of Atrial Fibrillation Laurent Haegeli University Hospital Zurich February 16, 2011 Willem Einthoven and Sir Thomas Lewis The first ECG in 1903 Willem Einthoven
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationCLINICAL OUTCOME OF AF ABLATION Who Benefits from Catheter Ablation?? Dr Gamal Shaban MD FESC Fellow of EHRA ECR AFA AFIB ALLIANCE NHI
CLINICAL OUTCOME OF AF ABLATION Who Benefits from Catheter Ablation?? Dr Gamal Shaban MD FESC Fellow of EHRA ECR AFA AFIB ALLIANCE NHI RHYTHM IS THE SOUL OF LIFE AF the last remaining challenge Considerable
More informationAblation of persistent AF Is it different than paroxysmal?
Ablation of persistent AF Is it different than paroxysmal? Steven J. Kalbfleisch, MD Medical Director Electrophysiology Laboratory Ohio State University Wexner Medical Center Ross Heart Hospital Columbus,
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationPatient Presentation
Update on Current Perspectives and Management Options for Atrial Fibrillation Burr Hall, M.D. March 20, 2015 Patient Presentation 72 year old active male farmer and tow truck operator from Hemlock, NY
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More informationCatheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD
Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD Taipei Veterans General Hospital, Taiwan Outline of AF Ablation 1. Strategy for Catheter Ablation of AF 2. Substrate
More informationDebate-STAR AF 2 study. PVI is not enough
Debate-STAR AF 2 study PVI is not enough Debate about STAR AF 2 trial STAR AF trial Substrate and Trigger Ablation for Reduction of Atrial Fibrillation EHJ 2010 STAR-AF 2 trial One Size Fits All? PVI is
More informationConcept, Challenges, Uptake and Adoption of Atrial Fibrillation Ablation: An Academic View. Douglas L. Packer MD Silver Springs, MD April 27, 2009
Concept, Challenges, Uptake and Adoption of Atrial Fibrillation Ablation: An Academic View Douglas L. Packer MD Silver Springs, MD April 27, 2009 Presenter Disclosure Information Catheter Ablation for
More informationTrattamento interventistico
Fibrillazione Atriale Trattamento interventistico Milano 5/10/18 Prof. Fiorenzo Gaita University of Turin Mechanisms of AF Trigger Atrial premature contractions (P/T) AF Substrate Anatomical: Critical
More informationCatheter Ablation of Atrial Fibrillation in Patients with Prosthetic Mitral Valve
Catheter Ablation of Atrial Fibrillation in Patients with Prosthetic Mitral Valve Luigi Di Biase, MD, PhD, FHRS Senior Researcher Texas Cardiac Arrhythmia Institute at St. David s Medical Center, Austin,
More informationPossible clinical and hemodynamic predictors of atrial fibrillation recurrence after catheter ablation
Samara Regional Center of Cardiosurgery Possible clinical and hemodynamic predictors of atrial fibrillation recurrence after catheter ablation S. Dolginina, S. Garkina, S. Khokhlunov, D. Duplyakov Russia
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More informationCatheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA
Catheter Ablation of Recurrent Ventricular Tachycardia Should Be Done Before Antiarrhythmic Therapy with Amiodarone is Tried CONTRA Erik Wissner, MD, F.A.C.C. Director - Magnetic Navigation Laboratory
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationThe HISTORIC-AF TRIAL
European Prospective Multicenter Study of Hybrid Thoracoscopic and Transcatheter Ablation of Persistent Atrial Fibrillation: The HISTORIC-AF TRIAL Claudio Muneretto 1, Gianluigi Bisleri 1, Gianluca Polvani
More informationLong-Term Atrial Fibrillation Progression: What We Know in 2014
Long-Term Atrial Fibrillation Progression: What We Know in 2014 Advances in Cardiac Arrhythmias and Great Innovations in Cardiology XXVI Giornate Cardiologiche Torinesi Turin, 23-25 October 2014 Davide
More informationPRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE. PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute
PRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute Background - Forms of Atrial Fibrillation - Clinical type of AF: + paroxysmal
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationIndications for catheter ablation in 2010: Ventricular Tachycardia
Indications for catheter ablation in 2010: Ventricular Tachycardia Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology Laboratories Ospedale San Raffaele, IRCCS, Milan, Italy Europace
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationCatheter ablation in AF patients with heart failure. What is possible?
Catheter ablation in AF patients with heart failure What is possible? Sébastien Knecht, MD PhD Hôpital cardiologique du Haut L Evêque, Bordeaux HEART FAILURE AND AF Ehrlich. JCE 2002 (13): 399-405, Wang
More informationTrial design and selection criteria
Background Cox-MAZE open chest, cardiac surgery was a very successful invasive procedure for treatment of AF 1, but highly invasive Since the landmark trial by Haissaguerre et al. 2, PV isolation by catheter
More informationAF in Andrew Staniforth. Mayo Course March 2014
AF in 2014 Andrew Staniforth Mayo Course March 2014 European Heart Journal 2010; 31: 2369 2429 www escardio.org/guidelines Q1 (Indications for anticoagulation) For stroke prevention in AF, which of the
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationWho Gets Atrial Fibrilla9on..?
Birmingham October 20 th 2013 AFA Pa9ents Day Symptoma9c Atrial Fibrilla9on What therapies are available? GENERAL BACKGROUND Andrew Grace Papworth Hospital and University of Cambridge Consultant: Medtronic
More informationRaphael Rosso MD, Yuval Levi Med. Eng., Sami Viskin MD Tel Aviv Sourasky Medical Center
Radiofrequency Ablation of Atrial Fibrillation: Comparison of Success Rate of Circular Ablation vs Point-by-Point Ablation with Contact Force Assessment in Paroxysmal and Persistent Atrial Fibrillation
More informationOutcomes of AF Ablation
2017 춘계심혈관통합학술대회 AF Summit: Atrial Fibrillation Apr.21(Fri) 14:40-16:10 Rm.300B 15:00-15:10 Outcomes of AF Ablation Gi-Byoung Nam MD Asan Medical Center, UUCM 2017 Annual Spring Scientific Conference of
More informationCatheter ablation of AF Where do we stand, where do we go?
Catheter ablation of AF Where do we stand, where do we go? Sébastien Knecht MD, PhD Hôpital cardiologique du Haut L Evêque, Bordeaux Declaration of conflict of interest ABLATION STRATEGIES Duration proc:
More informationDipen Shah Cardiology Service, University Hospitals, Geneva Switzerland
Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,
More informationCatheter Ablation for AF: Patients, Procedures, Outcomes
Catheter Ablation for AF: Patients, Procedures, Outcomes John Sapp Director Heart Rhythm, QEII Health Sciences Centre Professor of Medicine, Dalhousie University Atrial Fibrillation Atrial Fibrillation
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationCatheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF?
: Another Option for AF Atrial fibrillation (AF) is a highly common cardiac arrhythmia and a major risk factor for stroke. In this article, Dr. Khan and Dr. Skanes detail how catheter ablation significantly
More informationFibrillation Atriale Paroxystique : ablation, résultats, complications
Fibrillation Atriale Paroxystique : ablation, résultats, complications DIU Rythmologie Paris, le 27/01/16 sboveda@clinique-pasteur.com 1 A disease with bad consequences RR de patients en FA comparé avec
More informationAblation Update and Case Studies. Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group
Ablation Update and Case Studies Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group Disclosures No financial relationships to disclose Objectives At the conclusion of this activity,
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationStoria dell ablazione della fibrillazione atriale: da dove siamo partiti, dove siamo, dove andremo. Prof. Fiorenzo Gaita
Storia dell ablazione della fibrillazione atriale: da dove siamo partiti, dove siamo, dove andremo Prof. Fiorenzo Gaita Knowledge Idea Serendipity Technology (right tools) Serendipity - discovery of a
More informationContemporary Strategies for Catheter Ablation of Atrial Fibrillation
Contemporary Strategies for Catheter Ablation of Atrial Fibrillation Suneet Mittal, MD Director, Electrophysiology Medical Director, Snyder Center for Atrial Fibrillation The Arrhythmia Institute at The
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAtrial Fibrillation Ablation: in Whom and How
Update on Consensus Statement on Management of Atrial Fibrillation: EHRA 2012 Atrial Fibrillation Ablation: in Whom and How Update of HRS/EHRA AF/ECAS Ablation Document 2012 Anne M Gillis MD FHRS Professor
More information3/25/2017. Program Outline. Classification of Atrial Fibrillation
Alternate Strategies to Antiarrhythmic Therapy: The Role of Ablation Jennifer El Aile, MS, AGPCNP-BC Electrophysiology Nurse Practitioner Clinical Lecturer at the University of Michigan Program Outline
More informationDisclosures. Managing Atrial Fibrillation in Atrial Fibrillation: A Growing Problem. Objectives. Atrial Fibrillation: Prevalence Estimates
Managing Atrial Fibrillation in 2010 Jennifer Cummings, MD FACC Director, Cardiac Electrophysiology Akron General Medical Center Disclosures Company Boston Scientific St. Jude Medical Medtronic Sanofi-Aventis
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationAtrial Fibrillation: Interventional Approaches
Atrial Fibrillation: Interventional Approaches Tyler Taigen, MD Eric Espinal, MD Discussion Outline Review current treatment of atrial fibrillation Pathophysiology Risk assessment and treatment to reduce
More informationLong-Term ECG Monitoring Using an ILR. Evgeny Pokushalov, MD, PhD
Long-Term ECG Monitoring Using an ILR Evgeny Pokushalov, MD, PhD Long- Term ECG Monitoring Using an ILR Evgeny Pokushalov, MD, PhD, FESC State Research Ins;tute of Circula;on Pathology, Novosibirsk, Russia
More informationLong Standing Persistent AF ; CPVI is enough for it
Long Standing Persistent AF ; CPVI is enough for it Kee-Joon Choi, MD University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Boston AF Symposium 2012 In a patient undergoing AF ablation
More informationLinear Ablation Should Not Be a Standard Part of Ablation in Persistent AF. Disclosures. LA Ablation vs. Segmental Ostial Ablation With PVI for PAF
Linear Ablation Should Not Be a Standard Part of Ablation in Persistent AF The CA Heart Rhythm Symposium September 7, 2012 Gregory K. Feld, MD Professor of Medicine Director, Cardiac EP Program University
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationA Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC
A Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC AF Clinical/Referral Challenge Asymptomatic 40% 3 Rx Effective 30% Failed Rx Ablation Atrial fibrillation (AF) is the most common Candidate
More information480 April 2004 PACE, Vol. 27
Incremental Value of Isolating the Right Inferior Pulmonary Vein During Pulmonary Vein Isolation Procedures in Patients With Paroxysmal Atrial Fibrillation HAKAN ORAL, AMAN CHUGH, CHRISTOPH SCHARF, BURR
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationAtrial Fibrillation. Wat ur di-n 2 no. Ned Gutman 6 August, 2009
Atrial Fibrillation Wat ur di-n 2 no Ned Gutman 6 August, 2009 2 goals in treating AF Alleviation of symptoms Reduce risk of stroke Anticoagulation CHADS score Future anticoagulants Rate vs Rhythm control
More informationUNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate
KPAF trial The Kansai Plus Atrial Fibrillation (KPAF) trial is a 2x2 factorial randomized controlled trial, composed of the UNDER-ATP and EAST-AF trials. Efficacy of adenosine triphosphate guided ablation
More informationAF ablation Penn experience. Optimal approach to the ablation of PAF: Importance of identifying triggers 9/25/2009
Optimal approach to the ablation of PAF: Importance of identifying triggers David J. Callans, MD University of Pennsylvania School of Medicine AF ablation Penn experience Antral (circumferential) PV ablation
More informationComparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation Executive Summary
Number 15 Effective Health Care Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation Executive Summary Background The Agency for Healthcare Research and Quality commissioned
More informationAF ABLATION Concepts and Techniques
AF ABLATION Concepts and Techniques Antony F Chu, M.D. Director of Complex Ablation Arrhythmia Services Section Division of Cardiology at the Rhode Island and Miriam Hospital HIGHLIGHTS The main indications
More informationFocus on the role of Catheter Ablation: Simple cases Intermediate level Difficult cases (and patients) Impossible (almost )
22nd SHA Scientific Session 21 24 February 2011, Riyadh, KSA Management of Ventricular Arrhythmias: an Overview Corrado Carbucicchio Ventricular Intensive Care Unit Cardiac Arrhythmias Research Centre
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationManagement of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim
a holistic view - Prof. Dr. Martin Borggrefe Mannheim Patients with atrial fibrillation (millions) 16 14 12 10 8 6 4 2 0 Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9
More informationComplications During Cardiovascular Interventions: Management and Prevention
Complications During Cardiovascular Interventions: Management and Prevention Helmut Pürerfellner, MD Public Hospital Elisabethinen Academic Teaching Hospital Linz, Austria Atrial Tachycardia/Atypical left
More informationCatheter ablation is not a class I indication after failed antiarrhythmic drugs
Catheter ablation is not a class I indication after failed antiarrhythmic drugs Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationHigh density substrate mapping In AF
High density substrate mapping In AF A Pisapia J Seitz C Bars M Bremondy A Ferracci * J Khalifa ** * St Joseph Hospital Marseille ** Ann Arbor University Turin 2016 Hôpital Saint Joseph Marseille jseitz@hopital-saint-joseph.fr
More informationIndicatie voor ablatie bij voorkamerfibrillatie. Andrea Sarkozy Cardiologie Universitair Ziekenhuis Antwerpen
Indicatie voor ablatie bij voorkamerfibrillatie Andrea Sarkozy Cardiologie Universitair Ziekenhuis Antwerpen Definition and Classification of AF - Practical aspects Classification of AF Paroxysmal, persistent,
More informationAtrial Fibrillation: Guidelines through clinical cases and 2010 updates
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology World incidence 720, 000 new cases / year World prevalence 5.5 million
More informationStand alone maze: when and how?
Stand alone maze: when and how? Dong Seop Jeong Department of Thoracic and Cardiovascular Surgery, HVSI Samsung Medical Center Type of atrial fibrillation First diagnose AF Paroxysmal AF: self-terminating
More informationIncidence and Disease Burden. Role of Catheter ablation Outcomes Data
Management of Atrial Fibrillation Nitish Badhwar, MD, FACC University of California, San Francisco Risk Appraisal Forum April 23, 2010 Incidence and Disease Burden Drug therapy Role of Catheter ablation
More informationName of Policy: Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins as a Treatment of Atrial Fibrillation
Name of Policy: Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins as a Treatment of Atrial Fibrillation Policy #: 283 Latest Review Date: June 2014 Category: Medical Policy Grade: A
More information5/5/2010. World incidence 720, 000 new cases / year. World prevalence 5.55 million AF prevalence increasing with aging of population
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology UK World incidence 720, 000 new cases / year World prevalence 5.55
More informationManagement of Atrial Fibrillation in Heart Failure
Management of Atrial Fibrillation in Heart Failure Hani Sabbour MD FACC FHRS FASE Clinical Assistant Professor of Cardiology Brown University, Warren Alpert School of Medicine Rhode Island, USA Consultant
More information2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist
2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist Todays Objectives Atrial Fibrillation evaluation and treatment from an EP perspective Multimodal
More informationABLATION TECHNIQUES FOR ATRIAL FIBRILLATION
ABLATION TECHNIQUES FOR ATRIAL FIBRILLATION Demosthenes G. Katritsis, MD, PhD(Lon), FRCP Athens Euroclinic Ablation for AF Cox JL, et al. Surgery for atrial fibrillation. Semin Thorac Cardiovasc Surg.
More informationState of the Art Management on Atrial Fibrillation in Monica Lo, MD, FACC, FHRS April 15, 2016
State of the Art Management on Atrial Fibrillation in 2016 Monica Lo, MD, FACC, FHRS April 15, 2016 Scope of the Problem More than 30 million people worldwide 1 5 million new cases each year 1 in 4 lifetime
More informationTreatment of atrial fibrillation in patients with advanced heart failure - Rhythm or rate control: how to decide?
Treatment of atrial fibrillation in patients with advanced heart failure - Rhythm or rate control: how to decide? Uta C. Hoppe Dep. of Internal Medicine III University of Cologne No conflict of interest
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationAblation of long-standing AF. Is it wise to pursue it?
Ablation of long-standing AF. Is it wise to pursue it? Carlo Pappone, MD and Vincenzo Santinelli, MD From: Department of Arrhythmology,GVM Care and Research, Cotignola, Ravenna, ITALY Address for correspondence:
More information